Results 101 to 110 of about 164,371 (301)

Cancer Medicine and Precision Oncology [PDF]

, 2017
Cancer has garnered increasing interest among philosophers. This chapter focuses on cancer medicine and precision oncology, an influential approach to cancer which seeks to individualize treatment on the basis of genetic or molecular features of disease.
Chin-Yee, Benjamin
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Editorial: Precision Medicine in Spinal Oncology

Global Spine Journal
This special focus issue from the 2023-2024 AOSpine Knowledge Forum Tumor represents a culmination of years of experience devoted to advancing the care of patients with both metastatic and primary spinal tumors. We have learned much since the fundamental
Arjun Sahgal MD, Laurence Rhines MD
doaj   +1 more source

Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives

Cells
Precision oncology is broadly defined as cancer prevention, diagnosis, and treatment specifically tailored to the patient based on his/her genetics and molecular profile.
Diane Qiao, Richard C. Wang, Zhixiang Wang   +2 more
doaj   +1 more source

Precision Oncology

Abstract The implementation of precision oncology (PO) in Africa, which stands as a transformative approach tailoring treatments based on patient genetic profile and/or tumour molecular characteristics, remains challenging. This chapter presents an in-depth review of the current state of PO across Africa, delving into key components ...
Yosr Hamdi, Kais Ghedira, Yasmina Jaufeerally Fakim, Maroua Boujemaa, Rania Sibira, Marwa Matboli, Faisal M. Fadlelmola   +6 more
openaire   +1 more source

Addressing the challenges of applying precision oncology

, 2017
Precision oncology is described as the matching of the most accurate and effective treatments with the individual cancer patient. Identification of important gene mutations, such as BRCA1/2 that drive carcinogenesis, helped pave the way for precision ...
Ann M. Bode, Seung Ho Shin, Zigang Dong
core   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Current Bioinformatics Tools in Precision Oncology

MedComm
Integrating bioinformatics tools has profoundly transformed precision oncology by identifying essential molecular targets for personalized treatment. The rapid development of high‐throughput sequencing and multiomics technologies creates complex datasets
Tesfaye Wolde, Vipul Bhardwaj, Vijay Pandey   +2 more
doaj   +1 more source

Discordances between molecular profiling and precision oncology drug selection of non-small cell lung cancer in China

The Lancet Regional Health. Western Pacific
Background: Precision oncology drugs are a class of targeted drugs that are most effective in a molecularly defined subset of cancer patients. Pretreatment molecular profiling is integral to optimal patient selection.
Caiying Wu, Gengchen Wang, Xiaowen Hu, Shiyu Zhang, Xindi Liu, Xue Wang, Jingtao Liu, Wei Liu, Xu Ma, Xiaoyan Nie, Xiaodong Guan   +10 more
doaj   +1 more source

Future paradigms for precision oncology

Oncotarget, 2016
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic.
Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovács, Gábor, Kiss C, Norga K, Konstantinov D, Andre N, Slavc I, Berg HV, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J   +22 more
openaire   +5 more sources